Article

Omeros drug ready for FDA, CHMP review

Omeros Corp. has announced that the new drug application (NDA) for its new product, OMS302, has been confirmed for filing by the FDA.

 

Seattle-Omeros Corp. has announced that the new drug application (NDA) for its new product, OMS302, has been confirmed for filing by the FDA.

The marketing authorization application (MAA) for the drug has also been validated by the European Medicines Agency (EMA), and is ready for formal review by Europe’s Committee for Medicinal Products for Human Use (CHMP).

Omeros is seeking approval of the drug for use during IOL replacement surgery for the maintenance of intraoperative mydriasis, prevention of intraoperative miosis, and reduction of postoperative ocular pain.

The NDA will undergo FDA’s standard review, and the MAA has been designated for EMA’s centralized procedure in which recommendation for approval by CHMP would cover approval for marketing of the drug across the European Union and other countries in the European Economic Area.

“The acceptance for filing of our NDA by the FDA and validation of our MAA by the EMA mark important milestone on the path toward the commercial launch of (the drug) expected in 2014,” said Gregory A. Demopulos, MD, chairman and chief executive officer of Omeros.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
© 2025 MJH Life Sciences

All rights reserved.